Changgeng Fu

Notoginsenoside R1 Protects HUVEC Against Oxidized Low Density Lipoprotein (Ox-LDL)-Induced Atherogenic Response via Down-Regulating miR-132

Changgeng Fu, Dexin Yin, Haiying Nie et al. · Cellular Physiology and Biochemistry · 2018 · 34 citations · Full text

Xinyue Capsule in patients with stable coronary artery disease after percutaneous coronary intervention: a multicenter, randomized, placebo-controlled trial

Ming Guo, Peili Wang, Jianpeng Du et al. · Pharmacological Research · 2020 · 30 citations

Percutaneous Coronary Intervention, Cardiovascular Disease, Clinical Trials +7

Silence of lncRNA UCA1 Represses the Growth and Tube Formation of Human Microvascular Endothelial Cells Through miR-195

Dexin Yin, Changgeng Fu, Dajun Sun · Cellular Physiology and Biochemistry · 2018 · 27 citations · Full text

Resting heart rate associates with one-year risk of major adverse cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention

Shao-Li Wang, Chenglong Wang, Peili Wang et al. · Experimental Biology and Medicine · 2015 · 25 citations · Full text

Combination of Chinese Herbal Medicines and Conventional Treatment versus Conventional Treatment Alone in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention (5C Trial): An Open-Label Randomized Controlled, Multicenter Study

Shao-Li Wang, Chenglong Wang, Peili Wang et al. · Evidence-based Complementary and Alternative Medicine · 2013 · 23 citations · Full text

Heart Failure, Pharmacotherapy, Coronary Artery Disease +18